Byetta news from FiercePharma
NewsNovo drug bests Byetta in ADA study
SPOTLIGHT: Novo drug bests Byetta in ADA studyAmylin Pharmaceuticals' stock is suffering from a Novo Nordisk study that showed its experimental diabetes drug liraglutide outperformed Amylin's Read more...
ALSO NOTED: Bayer sues Watson over Yasmin; Zimmer weeds out doc conflicts
> Open another chapter in the Bayer fight to protect Yasmin patents: Watson Pharmaceuticals filed for FDA approval for its copycat version of the birth control pill, and Bayer sued to keep the Read more...
Lilly declares a truce in diabetes rep war
For a while there it looked like Eli Lilly and Novo Nordisk were competing to see who could deploy the biggest army of diabetes reps in the U.S. While most pharma companies were chopping sales Read more...
Lilly predicts double-digit earnings growth
Here's one bright spot today: Eli Lilly predicts a big year in 2008, with 14 percent growth in net profits and seven billion-dollar-plus products. Higher sales of drugs for depression (Read more...
8. Byetta - Top 10 Drug Warnings and Recalls
Drug: Byetta 2006 sales: $430 million Manufacturer: Amylin Safety concern: Precautionary language , pancreatitis Related Articles: > Lilly diabetes med linked to pancreatitis. Read more...
Amylin data doesn't impress Wall Street
It's good data, but is it good enough? Amylin Pharmaceuticals announced that its once-a-week version of the diabetes drug Byetta works better than the twice-a-day version now on the market. It was Read more...
Lilly diabetes med linked to pancreatitis
A fast-growing Eli Lilly med may be held back by a new warning linking it to acute pancreatitis. After 30 reports of pancreatitis in patients using the injectable diabetes drug Byetta--five of which Read more...
| Press ReleasesPRESS RELEASE: Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study - Both Groups Experienced Significant Weight Loss - - New Drug Application Filing Read more... PRESS RELEASE: Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study - Both Groups Experienced Significant Weight Loss - - New Drug Application Filing Read more... |
Get more Byetta coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends